Author Login

Correspondence to Author: Zeeshan Abbas^1*, Faisal Nawaz²,Syed Waqas Hassan¹. 

1. Department of Biosciences, University of Wah, Wah, Pakistan.
2. Department of Chemistry, University of Wah, Wah, Pakistan.

DOI: 10.52338/tejoc.2025.4681

Abstract:

As a mutation and genetics-dependent disease Prostate Cancer (PCa) ranks second among all male malignancies while remaining a dominant cause of male cancer fatalities. The BRCA1 and BRCA2 genes work to repair DNA but mutations in these genes make patients more vulnerable to tough types of PCa. BRCA2 mutations increase PCa risk four times more than other mutations including BRCA1 mutations. The tumors with these mutations display good responses to DNA-damaging drugs especially PARP inhibitors that exploit dysfunctional DNA repair mechanisms. Medical research teams connecting traditional herbal meds and modern science have demonstrated cancer fighting potential in many developing nations. Men should prioritize genetic screening due to its role in producing prostate cancer most commonly through abnormalities of important genes such as BRCA1 and BRCA2. A modified state of DNA repair genes leaves the body susceptible to the development of aggressive types of prostate cancer. Research shows that males carrying BRCA2 mutations will develop prostate cancer. DNA-damaging treatments such as PARP inhibitors will enhance the sensitivity of cancers which carry BRCA mutations. Targeting the dysfunctional DNA repair systems of cancer cells enables these medications to direct therapeutic action more precisely which results in improved patient results. Traditional herbal cancer treatment options show growing potential for medical use. Subsequent research will aim to clarify these organic substances' operational mechanisms which will develop new treatment methods combining modern medical science with existing medical knowledge.

Keywords:Prostate Cancer (PCa), BRCA, DNA Damage Response, Herbal Medicine, Phytochemicals, Anticancer.

Citation:

Zeeshan Abbas, Advances in In-Silico Analysis of Bioactive Compounds: Metabolic Interactions with genes involved in Prostate Cancer. The European Journal of Cancer 2025.